US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
US6639061B1
(en)
|
1999-07-07 |
2003-10-28 |
Isis Pharmaceuticals, Inc. |
C3′-methylene hydrogen phosphonate oligomers and related compounds
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
AU4155696A
(en)
|
1994-11-09 |
1996-06-06 |
Regents Of The University Of California, The |
Immunoliposomes that optimize internalization into target cells
|
CA2589421C
(en)
|
1996-03-27 |
2012-12-18 |
Genentech, Inc. |
Erbb3 antibodies
|
ES2274537T5
(es)
|
1996-03-27 |
2015-09-14 |
Genentech, Inc. |
Anticuerpos ErbB3
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
EP0938556B1
(en)
|
1996-07-12 |
2005-03-09 |
Genentech, Inc. |
Gamma-heregulin
|
US20020002276A1
(en)
|
1997-02-10 |
2002-01-03 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
US6723694B1
(en)
|
1997-05-21 |
2004-04-20 |
The Children's Medical Center Corp. |
Short peptides which selectively modulate intracellular signalling
|
US6416168B1
(en)
|
1997-07-15 |
2002-07-09 |
Silverbrook Research Pty Ltd |
Pump action refill ink jet printing mechanism
|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
AU2003203831B2
(en)
|
1998-02-04 |
2006-08-10 |
Genentech, Inc. |
Use of heregulin as an epithelial cell growth factor
|
ES2229679T3
(es)
|
1998-02-04 |
2005-04-16 |
Genentech, Inc. |
Utilizacion de heregulina como factor de crecimiento de celulas epiteliales.
|
US20010023241A1
(en)
|
1998-02-04 |
2001-09-20 |
Sliwkowski Mark X. |
Use of heregulin as a growth factor
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
DK2016951T3
(da)
|
1998-03-17 |
2012-09-24 |
Genentech Inc |
VEGF- og BMP1-homologe polypeptider
|
ES2340112T3
(es)
|
1998-04-20 |
2010-05-28 |
Glycart Biotechnology Ag |
Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
|
AU2004200705A1
(en)
|
1998-05-15 |
2004-03-18 |
Imclone Systems Incorporated |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
PL348634A1
(en)
|
1998-05-15 |
2002-06-03 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
EP1126873A1
(en)
|
1998-11-07 |
2001-08-29 |
Genentech, Inc. |
Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
JP2002544123A
(ja)
*
|
1999-04-14 |
2002-12-24 |
スミスクライン・ビーチャム・コーポレイション |
エリトロポイエチン受容体抗体
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
US6710186B2
(en)
|
1999-06-14 |
2004-03-23 |
Wisconsin Alumni Research Foundation |
Oligomers and polymers of di-substituted cyclic imino carboxylic acids
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
WO2001000244A2
(en)
|
1999-06-25 |
2001-01-04 |
Genentech, Inc. |
METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
|
DE10084743T1
(de)
|
1999-06-25 |
2002-08-14 |
Genentech Inc |
Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern
|
TR200200472T2
(tr)
|
1999-08-27 |
2002-06-21 |
Genentech, Inc. |
Anti-Erb B2 antikorları ile tedavi için dozajlar
|
US7732157B1
(en)
|
1999-09-30 |
2010-06-08 |
Tumor Biology Investment Group |
Soluble epidermal growth factor receptor-like proteins and their uses in cancer detection methods
|
US7390632B2
(en)
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
US7651703B2
(en)
|
1999-10-15 |
2010-01-26 |
Genentech, Inc. |
Injection vehicle for polymer-based formulations
|
WO2001051924A2
(en)
|
2000-01-12 |
2001-07-19 |
Ventana Medical Systems, Inc. |
Method for determining the response to cancer therapy
|
IL150755A0
(en)
|
2000-02-16 |
2003-02-12 |
Genentech Inc |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
AU2007216733A1
(en)
|
2000-04-11 |
2007-09-27 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
KR20020093029A
(ko)
|
2000-04-11 |
2002-12-12 |
제넨테크, 인크. |
다가 항체 및 그의 용도
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
AUPQ903400A0
(en)
|
2000-07-27 |
2000-08-17 |
Oh, Young June |
Navigable search engine
|
US6277640B1
(en)
|
2000-07-31 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of Her-3 expression
|
ATE356575T1
(de)
|
2000-11-24 |
2007-04-15 |
Freudenberg Carl Kg |
Bodenwischer
|
AU2008200400B2
(en)
|
2001-01-17 |
2012-06-07 |
Aptevo Research And Development Llc |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
EP1228766A1
(en)
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
EP1370588A2
(en)
|
2001-02-12 |
2003-12-17 |
Medarex, Inc. |
Human monoclonal antibodies to fc alpha receptor (cd89)
|
US7638598B2
(en)
|
2001-04-06 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
ErbB interface peptidomimetics and methods of use thereof
|
WO2002087618A1
(fr)
|
2001-04-27 |
2002-11-07 |
Takeda Chemical Industries, Ltd. |
Methode de prevention et de traitement du cancer
|
WO2002095356A2
(en)
|
2001-05-21 |
2002-11-28 |
Aclara Biosciences, Inc. |
Methods and compositions for analyzing proteins
|
US7745398B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 and treatment of cancer
|
US7744882B2
(en)
|
2001-05-31 |
2010-06-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 methods of detection and antibodies
|
JP2005500034A
(ja)
|
2001-06-20 |
2005-01-06 |
プロション バイオテク リミテッド |
受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
|
WO2003001602A2
(en)
|
2001-06-21 |
2003-01-03 |
Akzo Nobel N.V. |
Manufacturing a solar cell foil connected in series via a temporary substrate
|
WO2003011897A1
(en)
|
2001-07-27 |
2003-02-13 |
The Regents Of The University Of California |
Modulation of heregulin and her3 interaction
|
DE10137374A1
(de)
|
2001-07-31 |
2003-02-27 |
Ipk Inst Fuer Pflanzengenetik |
Verfahren zur Herstellung von Arachidonsäure in transgenen Organismen
|
AU2002326531A1
(en)
|
2001-08-03 |
2003-02-17 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbb family members and methods of use thereof
|
AU2008200654B2
(en)
|
2001-08-09 |
2010-04-29 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Inhibitors of HER3 activity
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
WO2005063299A2
(en)
|
2003-12-24 |
2005-07-14 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
JP4132912B2
(ja)
|
2002-03-26 |
2008-08-13 |
日東電工株式会社 |
ゲル電解質とその製造方法とその利用
|
US7919098B2
(en)
|
2002-03-26 |
2011-04-05 |
Zensun ( Shanghai ) Sci & Tech Co., Ltd. |
ErbB-3 based methods and compositions for treating neoplasms
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
WO2003102132A2
(en)
|
2002-04-26 |
2003-12-11 |
Genetech, Inc. |
Non-affinity purification of proteins
|
US20040229299A1
(en)
|
2002-05-21 |
2004-11-18 |
Badal M. Youssouf |
Intracellular complexes as biomarkers
|
US20040229380A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
US20040229294A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB surface receptor complexes as biomarkers
|
US20040229293A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
Surface receptor complexes as biomarkers
|
AU2003251597A1
(en)
|
2002-06-19 |
2004-01-06 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
CA2490758C
(en)
|
2002-07-15 |
2014-09-23 |
Genentech, Inc. |
Dosage form of recombinant humanized monoclonal antibody 2c4
|
WO2004011900A2
(en)
|
2002-07-25 |
2004-02-05 |
Aclara Biosciences, Inc. |
Detecting receptor oligomerization
|
GB0225282D0
(en)
|
2002-10-31 |
2002-12-11 |
Astrazeneca Ab |
assay
|
CA2513113A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
BRPI0409554A
(pt)
|
2003-04-04 |
2006-04-25 |
Univ Lausanne |
peptacorpo de fusão isolado e recombinante, seqüência de dna, vetor, célula hospedeira, composição farmacêutica e seu uso, kits, método para a produção do peptacorpo de fusão e seqüência de intensificador
|
WO2004094463A2
(en)
|
2003-04-18 |
2004-11-04 |
University Of Florida Research Foundation, Inc. |
Peptide inhibitors of autophosphorylation protein kinases
|
MXPA05012939A
(es)
|
2003-05-30 |
2006-05-17 |
Astrazeneca Uk Ltd |
Procedimiento.
|
ATE425463T1
(de)
|
2003-06-06 |
2009-03-15 |
Genentech Inc |
Modulation der wechselwirkung zwischen hgf-beta- kette und c-met
|
US20050232931A1
(en)
|
2003-06-13 |
2005-10-20 |
Oncomax Acquisition Corp. |
Preparation and application of anti-tumor bifunctional fusion proteins
|
US20040254108A1
(en)
|
2003-06-13 |
2004-12-16 |
Jing Ma |
Preparation and application of anti-tumor bifunctional fusion proteins
|
EP1633398A4
(en)
|
2003-06-13 |
2007-02-28 |
Oncomax Acquisition Corp |
PREPARATION AND APPLICATION OF BIFUNCTIONAL ANTI-TUMOR HYBRID PROTEINS
|
US6836094B1
(en)
|
2003-07-01 |
2004-12-28 |
International Truck Intellectual Property Company, Llc |
Motor vehicle battery disconnect switch circuits
|
US7531649B2
(en)
|
2003-07-18 |
2009-05-12 |
The Regents Of The University Of California |
Aptamers to human epidermal growth factor receptor-3
|
SI1648940T1
(sl)
|
2003-07-28 |
2016-08-31 |
Genentech, Inc. |
Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A
|
US20060281093A1
(en)
|
2003-08-05 |
2006-12-14 |
Richard Kim |
Erbb receptor methods and kits for monitoring chemotherapy resistance
|
WO2005014618A2
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
WO2005019470A2
(en)
|
2003-08-11 |
2005-03-03 |
Monogram Biosciences, Inc. |
Detecting and profiling molecular complexes
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
EP1681983A4
(en)
|
2003-10-14 |
2008-12-10 |
Monogram Biosciences Inc |
RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY
|
US20050130246A1
(en)
|
2003-10-27 |
2005-06-16 |
Hossein Salimi-Moosavi |
Detecting human anti-therapeutic antibodies
|
WO2005044302A1
(en)
|
2003-11-06 |
2005-05-19 |
Pfizer Products Inc. |
Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
|
US7754441B2
(en)
|
2003-11-17 |
2010-07-13 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
WO2006107617A2
(en)
|
2005-04-06 |
2006-10-12 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
WO2005079434A2
(en)
|
2004-02-17 |
2005-09-01 |
The University Of North Carolina At Chapel Hill |
Modulation of epidermal growth factor heterodimer activity
|
US7906624B2
(en)
|
2004-02-20 |
2011-03-15 |
The Trustees Of The University Of Pennsylvania |
Binding peptidomimetics and uses of the same
|
WO2005112969A2
(en)
|
2004-04-22 |
2005-12-01 |
Oregon Health And Science University |
Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors
|
WO2005117973A2
(en)
|
2004-05-05 |
2005-12-15 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
EP1784427A2
(en)
|
2004-06-01 |
2007-05-16 |
Domantis Limited |
Bispecific fusion antibodies with enhanced serum half-life
|
GT200500155A
(es)
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
US20070197430A1
(en)
|
2004-06-24 |
2007-08-23 |
Jonathan Baell |
Conjugates And Therapeutic Uses Thereof
|
KR20150043558A
(ko)
|
2004-07-22 |
2015-04-22 |
제넨테크, 인크. |
Her2 항체 조성물
|
AU2005286607B2
(en)
|
2004-09-23 |
2011-01-27 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
WO2006042002A2
(en)
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
CN102746404B
(zh)
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
CA2587894A1
(en)
|
2004-11-22 |
2006-06-01 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
|
US7947839B2
(en)
|
2004-12-01 |
2011-05-24 |
Genentech, Inc. |
Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
|
JP2008521907A
(ja)
*
|
2004-12-03 |
2008-06-26 |
シェーリング コーポレイション |
抗igf1r治療について患者を予め選択するためのバイオマーカー
|
CA2587519A1
(en)
|
2004-12-07 |
2006-06-15 |
Genentech, Inc. |
Selecting patients for therapy with a her inhibitor
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
CA2601700A1
(en)
|
2004-12-21 |
2006-06-29 |
Cell Signaling Technology, Inc. |
Protein phosphorylation in egfr-signaling pathways
|
RS50785B
(sr)
|
2005-01-05 |
2010-08-31 |
F-Star Biotechnologische Forschungs-Und Entwicklungsges M.B.H. |
Domeni sintetskih imunoglobulina sa svojstvima vezivanja, konstruisani u svojstvima molekula, koji se razlikuju od regiona, koji određuju komplementarnost
|
CA2593697A1
(en)
|
2005-01-11 |
2006-07-20 |
Molecular Logix, Inc. |
Pan-her antagonists and methods of use
|
CN102580084B
(zh)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
WO2006084018A2
(en)
|
2005-02-02 |
2006-08-10 |
Monogram Biosciences, Inc. |
Methods for determining responsiveness to cancer therapy
|
PL1871805T3
(pl)
|
2005-02-07 |
2020-03-31 |
Roche Glycart Ag |
Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
|
US7718626B2
(en)
|
2005-02-17 |
2010-05-18 |
University Of Maryland, Baltimore |
ErbB3 binding protein compositions and methods of use
|
SI1850874T1
(sl)
|
2005-02-23 |
2014-01-31 |
Genentech, Inc. |
Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
|
RU2007135216A
(ru)
|
2005-02-23 |
2009-03-27 |
Мерримак Фармасьютикалз, Инк. (Us) |
Биспецифические связывающие агенты для модулирования биологической активности
|
US7210618B2
(en)
|
2005-03-03 |
2007-05-01 |
Nokia Corporation |
Mobile communication terminal
|
KR20080004480A
(ko)
|
2005-03-07 |
2008-01-09 |
타게티드 몰레큘라 다이아그노스틱스, 엘엘씨 |
티로신 키나제 억제제 조성물, 그의 제조 방법 및 이를이용한 질병 치료 방법
|
TW200642695A
(en)
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
US20080171067A1
(en)
|
2007-01-17 |
2008-07-17 |
Immunomedics, Inc. |
Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites
|
PL1874821T3
(pl)
|
2005-04-26 |
2013-09-30 |
Trion Pharma Gmbh |
Kombinacja przeciwciał i glikokortykoidów do leczenia raka
|
EP1913160A2
(en)
|
2005-07-29 |
2008-04-23 |
Bayer Healthcare LLC |
Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
|
BRPI0615397B1
(pt)
|
2005-08-26 |
2023-10-03 |
Roche Glycart Ag |
Anticorpo anti-cd20, composição farmacêutica que o contém e uso do mesmo
|
WO2007038792A2
(en)
|
2005-09-28 |
2007-04-05 |
H. Lee Moffitt Cancer Center |
Individualized cancer treatments
|
EP1931709B1
(en)
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
US20090252681A1
(en)
|
2005-10-11 |
2009-10-08 |
Ablynx N.V. |
Nanobodies and Polypeptides Against EGFR and IGF-IR
|
US20110052570A1
(en)
|
2005-10-26 |
2011-03-03 |
Children's Medical Center Corporation |
Method to prognose response to anti-egfr therapeutics
|
EP1792622A1
(en)
|
2005-11-11 |
2007-06-06 |
GPC Biotech AG |
Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
|
EP1800695A1
(en)
|
2005-12-21 |
2007-06-27 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Immuno-RNA-constructs
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
WO2007089871A2
(en)
|
2006-02-01 |
2007-08-09 |
The Johns Hopkins University |
Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
|
KR101516823B1
(ko)
|
2006-03-17 |
2015-05-07 |
바이오겐 아이덱 엠에이 인코포레이티드 |
안정화된 폴리펩티드 조성물
|
US7897723B2
(en)
|
2006-04-07 |
2011-03-01 |
Københavns Universitet |
ErbB receptor-derived peptide fragments
|
BRPI0712077A2
(pt)
|
2006-05-01 |
2012-01-17 |
Genentech Inc |
prolongamento de sobrevivência de pacientes com cáncer com niveis elevados de egf ou tgf-alfa
|
CN101627053A
(zh)
*
|
2006-06-12 |
2010-01-13 |
西福根有限公司 |
泛细胞表面受体特异的治疗剂
|
US8409577B2
(en)
|
2006-06-12 |
2013-04-02 |
Emergent Product Development Seattle, Llc |
Single chain multivalent binding proteins with effector function
|
WO2007145832A2
(en)
|
2006-06-13 |
2007-12-21 |
Shulman Zachary J |
Infant harness support
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
WO2008019394A2
(en)
|
2006-08-11 |
2008-02-14 |
The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services |
Methods for treatment and diagnosis of psychiatric disorders
|
US8936780B2
(en)
|
2006-08-30 |
2015-01-20 |
Advanced Cardiovascular Systems, Inc. |
Stimuli responsive polyester amide particles
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
BRPI0715754A2
(pt)
|
2006-08-31 |
2013-07-09 |
Hoffmann La Roche |
mÉtodo para a produÇço de fator do crescimento similar Á insulina i
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
US9250243B2
(en)
|
2006-09-21 |
2016-02-02 |
Nestec S.A. |
Drug selection for lung cancer therapy using antibody-based arrays
|
KR101485303B1
(ko)
|
2006-09-21 |
2015-01-22 |
네스텍 소시에테아노님 |
희귀 순환세포 내의 다수의 신호전달인자를 검출하기 위한 항체 기반 분석법
|
BRPI0717416A2
(pt)
|
2006-09-21 |
2013-11-12 |
Prometheus Lab Inc |
Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
|
US20080112961A1
(en)
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
EP2092075A2
(en)
|
2006-11-06 |
2009-08-26 |
Source Precision Medicine, Inc. |
Gene expression profiling for identification, monitoring and treatment of melanoma
|
AU2007353412A1
(en)
|
2006-11-21 |
2008-11-20 |
Fox Chase Cancer Center |
Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
|
EP2097754B2
(en)
|
2006-11-28 |
2018-01-24 |
Daiichi Sankyo Europe GmbH |
Activated her3 as a marker for predicting therapeutic efficacy
|
SG177225A1
(en)
|
2006-12-01 |
2012-01-30 |
Agency Science Tech & Res |
Cancer-related protein kinases
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8163886B2
(en)
|
2006-12-21 |
2012-04-24 |
Emd Millipore Corporation |
Purification of proteins
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
PL2129396T3
(pl)
|
2007-02-16 |
2014-02-28 |
Merrimack Pharmaceuticals Inc |
Przeciwciała przeciw ERBB3 i ich zastosowania
|
AU2008223069B2
(en)
|
2007-03-02 |
2012-12-13 |
F. Hoffmann-La Roche Ag |
Predicting response to a HER dimerisation inhibitor based on low HER3 expression
|
PE20090190A1
(es)
|
2007-03-23 |
2009-03-22 |
Smithkline Beecham Corp |
Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
|
CN101636412A
(zh)
|
2007-03-30 |
2010-01-27 |
霍夫曼-拉罗奇有限公司 |
标记的和非标记的单克隆抗体的组合物
|
EP2076289B1
(en)
|
2007-04-13 |
2014-11-12 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
FR2915115B1
(fr)
|
2007-04-23 |
2010-09-10 |
Sames Technologies |
Organe de pulverisation,dispositif de projection comportant un tel organe,installation de projection et methode de nettoyage d'un tel organe
|
CA2688477C
(en)
|
2007-06-01 |
2020-12-22 |
The Regents Of The University Of California |
Multigene prognostic assay for lung cancer
|
AU2008258859A1
(en)
|
2007-06-06 |
2008-12-11 |
F.Hoffmann-La Roche Ag |
Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
|
US20100183504A1
(en)
|
2007-06-14 |
2010-07-22 |
Fanqing Frank Chen |
Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
|
JP2010531666A
(ja)
|
2007-06-26 |
2010-09-30 |
ユニバーシティ オブ マイアミ |
抗体−エンドスタチン融合タンパク質及びそのバリアント
|
WO2009003082A2
(en)
|
2007-06-26 |
2008-12-31 |
Vanderbilt University |
Immunological compositions as cancer biomarkers and/or therapeutics
|
DE17196350T1
(de)
|
2007-07-09 |
2018-12-27 |
Genentech, Inc. |
Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden
|
WO2009023266A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members
|
CN108129573B
(zh)
|
2007-09-21 |
2021-10-08 |
加利福尼亚大学董事会 |
被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
|
EP2205277B1
(en)
|
2007-10-22 |
2017-07-26 |
Genmab A/S |
Novel antibody therapies
|
EP2230300A4
(en)
|
2007-10-24 |
2012-08-08 |
Otsuka Chemical Holdings Co Ltd |
POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION
|
WO2009108637A1
(en)
|
2008-02-25 |
2009-09-03 |
Prometheus Laboratories, Inc. |
Drug selection for breast cancer therapy using antibody-based arrays
|
US20090226455A1
(en)
|
2008-03-06 |
2009-09-10 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
EP2106806A1
(en)
|
2008-03-31 |
2009-10-07 |
Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. |
Nanoparticles for targeted delivery of active agents to the lung
|
KR20110008086A
(ko)
|
2008-04-11 |
2011-01-25 |
메리맥 파마슈티컬즈, 인크. |
인간 혈청 알부민 링커 및 그 콘쥬게이트
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
WO2009134870A1
(en)
|
2008-04-30 |
2009-11-05 |
Immunogen, Inc. |
Potent cell-binding agent drug conjugates
|
SG189817A1
(en)
|
2008-04-30 |
2013-05-31 |
Immunogen Inc |
Potent conjugates and hydrophilic linkers
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
KR20110028450A
(ko)
|
2008-06-16 |
2011-03-18 |
이뮤노젠 아이엔씨 |
새로운 상승 효과
|
EP2138511A1
(en)
|
2008-06-27 |
2009-12-30 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
HER3 as a determinant for the prognosis of melanoma
|
MX2010014574A
(es)
*
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
AU2009273540A1
(en)
|
2008-07-25 |
2010-01-28 |
Merck Patent Gmbh |
Method of determination of receptor binding saturation effected by monoclonal antibodies
|
US8056451B2
(en)
|
2008-07-28 |
2011-11-15 |
Irwin Industrial Tool Company |
Locking pliers
|
US20100033482A1
(en)
|
2008-08-11 |
2010-02-11 |
Interactive Relighting of Dynamic Refractive Objects |
Interactive Relighting of Dynamic Refractive Objects
|
BRPI0917871A2
(pt)
|
2008-08-15 |
2017-06-20 |
Merrimack Pharmaceuticals Inc |
agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico
|
CN102216452B
(zh)
|
2008-09-26 |
2013-08-21 |
尤里卡治疗公司 |
具有变异糖基化方式的细胞系和蛋白质
|
EP2362783A2
(en)
|
2008-10-31 |
2011-09-07 |
Biogen Idec MA Inc. |
Light targeting molecules and uses thereof
|
EP3622968A1
(en)
|
2008-10-31 |
2020-03-18 |
The General Hospital Corporation |
Compositions and methods for delivering a substance to a biological target
|
US8927694B2
(en)
|
2008-11-18 |
2015-01-06 |
Merrimack Pharmaceuticals, Inc. |
Human serum albumin linkers and conjugates thereof
|
US8349574B2
(en)
|
2009-01-15 |
2013-01-08 |
Laboratory Corporation Of America Holdings |
Methods of determining patient response by measurement of Her-3
|
US20100169729A1
(en)
|
2008-12-30 |
2010-07-01 |
Datta Shamanna M |
Enabling an integrated memory controller to transparently work with defective memory devices
|
US20110306514A1
(en)
|
2009-01-14 |
2011-12-15 |
United States Department of Health and Human Services |
Ratio based biomarkers and methods of use thereof
|
SG172984A1
(en)
|
2009-01-15 |
2011-08-29 |
Lab Corp America Holdings |
Methods of determining patient response by measurement of her-2 expression
|
HRP20221259T1
(hr)
|
2009-02-13 |
2022-12-09 |
Immunomedics, Inc. |
Imunokonjugati s intracelularnom vezom koja se može rascijepiti
|
CN102326081B
(zh)
|
2009-02-24 |
2014-11-19 |
霍夫曼-拉罗奇有限公司 |
s-ErbB-3作为癌症标志物的应用
|
EP2400984A4
(en)
|
2009-02-25 |
2013-01-23 |
Merck Sharp & Dohme |
HER2 ANTIBODY COMPOSITIONS
|
MY152068A
(en)
|
2009-03-20 |
2014-08-15 |
Genentech Inc |
Bispecific anti-her antibodies
|
WO2010127181A1
(en)
*
|
2009-04-29 |
2010-11-04 |
Trellis Bioscience, Inc. |
Improved antibodies immunoreactive with heregulin-coupled her3
|
WO2010136569A1
(en)
|
2009-05-29 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
EP2445520A4
(en)
|
2009-06-22 |
2013-03-06 |
Medimmune Llc |
MANIPULATED FC REGIONS FOR LOCAL SPECIFIC CONJUGATION
|
AU2010273319B2
(en)
|
2009-07-15 |
2015-01-22 |
Nestec S.A. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
WO2011031397A1
(en)
|
2009-08-06 |
2011-03-17 |
Genentech, Inc. |
Method to improve virus removal in protein purification
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
MX336091B
(es)
|
2009-08-21 |
2016-01-08 |
Merrimack Pharmaceuticals Inc |
Anticuerpos contra el extodominio de erbb3 y usos de los mismos.
|
US20110059081A1
(en)
|
2009-09-09 |
2011-03-10 |
Quintiles Transnational Corp. |
Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
|
US9096877B2
(en)
|
2009-10-07 |
2015-08-04 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
JP2013507378A
(ja)
|
2009-10-09 |
2013-03-04 |
メルク・シャープ・エンド・ドーム・コーポレイション |
抗her3抗体の製造、特徴づけ及びその用途
|
CA2777242A1
(en)
|
2009-10-14 |
2011-04-21 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
JP5931736B2
(ja)
|
2009-11-13 |
2016-06-08 |
ウー3・フアルマ・ゲー・エム・ベー・ハーU3 Pharma |
Her−3関連疾患を治療または予防するための物質および方法
|
CN102892779B
(zh)
|
2010-02-18 |
2016-12-21 |
基因泰克公司 |
神经调节蛋白拮抗剂及其在治疗癌症中的用途
|
EP2542699A4
(en)
|
2010-03-03 |
2013-10-02 |
Targeted Molecular Diagnostics Llc |
METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
|
EP2859893A1
(en)
|
2010-03-11 |
2015-04-15 |
Merrimack Pharmaceuticals, Inc. |
Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
|
ES2566602T3
(es)
|
2010-04-09 |
2016-04-14 |
Aveo Pharmaceuticals, Inc. |
Anticuerpos anti-ErbB3
|
WO2011139629A2
(en)
|
2010-04-26 |
2011-11-10 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
US20130108547A1
(en)
|
2010-05-13 |
2013-05-02 |
Fox Chase Cancer Center |
Recombinantly Produced Antibodies Targeting ErbB Signaling Molecules and Methods of Use Thereof for the Diagnosis and Treatment of Disease
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US9932403B2
(en)
|
2010-05-20 |
2018-04-03 |
Ablynx Nv |
Biological materials related to HER3
|
AU2012211258A1
(en)
|
2011-01-27 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid stage tumors using anti-ErbB3 antibodies
|
MX355255B
(es)
|
2011-02-04 |
2018-04-11 |
Genentech Inc |
Variantes de fc y métodos para su producción.
|
WO2012106578A1
(en)
|
2011-02-04 |
2012-08-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc)
|
CA2826467C
(en)
|
2011-02-07 |
2019-11-12 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides
|
CA2829110C
(en)
|
2011-03-06 |
2019-01-15 |
Merck Serono S.A. |
Low fucose cell lines and uses thereof
|
EP3553527A1
(en)
|
2011-03-17 |
2019-10-16 |
Cernostics, Inc. |
Systems and compositions for diagnosing barrett's esophagus and methods of using the same
|